DOAC Dosing Guide
Apixaban (Eliquis®)
Dose Reduction Criteria: Reduce to 2.5mg BID if ≥2 of the following are met.
Age ≥ 80 years
Weight ≤ 60 kg
Serum Creatinine ≥ 1.5 mg/dL
Enter patient data
Please enter all parameters.
Note: Avoid co-administration with strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir).
Rivaroxaban (Xarelto®)
Please enter all parameters.
Note: The 15mg and 20mg tablets should be taken with food to ensure optimal absorption.
Edoxaban (Lixiana®/Savaysa®)
Please enter all parameters.
Note: Avoid use in patients with CrCl > 95 mL/min due to potentially reduced efficacy.
Dabigatran (Pradaxa®)
Please enter all parameters.
Note: Capsules must be swallowed whole and not opened, as this increases bleeding risk.
About This DOAC Renal Dosing Calculator
This DOAC renal dosing calculator is designed for healthcare professionals to facilitate accurate dosing for patients with non-valvular atrial fibrillation (NVAF). Proper dose adjustment based on renal function is critical to balance the prevention of ischemic stroke with the risk of major bleeding. This calculator automates the process by first calculating Creatinine Clearance (CrCl) and then applying guideline-based dosing criteria for the most common Direct Oral Anticoagulants (DOACs).
The Formula Explained
The Cockcroft-Gault formula is used to estimate CrCl. This is the recommended formula for a DOAC renal dosing calculator because it was used in the landmark clinical trials that established the dosing regimens for these drugs.
$$ \text{CrCl (mL/min)} = \frac{(140 – \text{Age}) \times \text{Weight (kg)} \times [0.85 \text{ if Female}]}{72 \times \text{Serum Creatinine (mg/dL)}} $$
Limitations
It is crucial to be aware of the limitations of this Creatinine Clearance Calculator. Its accuracy can be compromised in several populations, including: the elderly, individuals with very low or high Body Mass Index (BMI), pregnant women, and patients with unstable renal function or significant liver disease.
Frequently Asked Questions (FAQ)
1. Why use Cockcroft-Gault instead of CKD-EPI for DOAC dosing?
The pivotal clinical trials for apixaban, rivaroxaban, edoxaban, and dabigatran used the Cockcroft-Gault equation to define renal function categories for inclusion and dose adjustment. To remain consistent with the evidence from these trials, current guidelines recommend using Cockcroft-Gault for a DOAC renal dosing calculator.
2. What is the significance of CrCl > 95 mL/min for Edoxaban?
In the ENGAGE AF-TIMI 48 trial, patients with a CrCl > 95 mL/min receiving edoxaban had a higher rate of ischemic stroke compared to those on warfarin. It is thought that in patients with very good renal function, the drug is cleared too quickly, leading to reduced efficacy. Therefore, its use is generally avoided in this population.
3. Are these dosing recommendations valid for VTE treatment?
No. While the principles of renal adjustment are similar, the specific CrCl cutoffs and dosing recommendations can differ for the treatment of Venous Thromboembolism (VTE). This guide is specifically for the NVAF indication.
4. How do renal clearances differ among DOACs?
Dabigatran is the most reliant on renal clearance (~80%), making it highly sensitive to changes in kidney function. Rivaroxaban (~35%), Apixaban (~27%), and Edoxaban (~50%) are less dependent on the kidneys for elimination, but dose adjustments are still crucial.
5. What other factors should be considered beyond CrCl?
Always perform a holistic assessment. This includes checking for significant liver disease (most DOACs are contraindicated in severe hepatic impairment), potential drug-drug interactions (especially with strong P-gp and CYP3A4 inhibitors/inducers), and extremes of body weight, which can affect drug concentrations.
Related Calculators
⚠️ Disclaimer:
This tool is for informational and educational purposes only and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified healthcare professional considering the individual patient’s full clinical context.
